Institutional Ownership
Eagle Pharmaceuticals Inc
CUSIP 269796108COMEGRXQ1 2026
13D / 13G Filings
51
Schedule 13D/13G on record
Beneficial Filers
17
Distinct reporting persons
Largest Stake
38.1%
Max % of class reported
Institutional Holders
2
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
51 filings · latest Aug 14, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Aug 14, 2025 | J. Goldman &Amp; Co LP | 13G | 5.1% | 667.1K | SEC |
| 2 | Aug 14, 2025 | Nantahala Capital Management, LLC | 13G/A | 38.1% | 4.95M | SEC |
| 3 | Feb 19, 2025 | Nantahala Capital Partners Limited Partnership | 13G | 6.2% | 810.6K | SEC |
| 4 | Feb 19, 2025 | Nantahala Capital Management, LLC | 13G/A | 38.1% | 4.95M | SEC |
| 5 | Feb 14, 2025 | Union Square Park Partners, LP | 13G/A | 11.4% | 1.49M | SEC |
| 6 | Nov 14, 2024 | Janus Henderson Group PLC | 13G/A | — | — | SEC |
| 7 | Nov 14, 2024 | Brandes Investment Partners, LP | 13G/A | — | — | SEC |
| 8 | Nov 12, 2024 | Citigroup Inc | 13G | 7.7% | 1.00M | SEC |
| 9 | Nov 5, 2024 | Nantahala Capital Management, LLC | 13G/A | 30.4% | 3.95M | SEC |
| 10 | Oct 31, 2024 | Union Square Park Capital Management, LLC | 13G/A | 10.2% | 1.32M | SEC |
41 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Eagle Pharmaceuticals Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Stanley-Laman Group, Ltd. | 12.0K | $4.1K |
| 2 | Archer Investment Corp | 350 | $119 |